Orthocell Limited received a European patent for its pipeline `Cell Factory' technology which produces tissue specific growth factors and bioactive proteins to enhance tissue repair. Current growth factor approaches are generic and often result in a mix of growth factors not specific to the tissue that is being treated. Orthocell's patent issuance follows from the Cell Factory work for cartilage injuries that was first announced by Orthocell in May 2015 and for the inducement of bone formation first announced in April 2016.